Sandra Zetterström

Dr. Sandra Zetterström


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Equine Veterinary Science
Verified
Journal Article
Closed access
SZSandra Zetterström
Sandra Zetterström
EGErin Groover
Erin Groover
KLKara Lascola
Kara Lascola
RCRobert Cole
Robert Cole
AAAna Velloso Alvarez
Ana Velloso Alvarez
LBLindsey Boone
Lindsey Boone

3 March 2021 in Equine Veterinary Education
Verified
Journal Article
Closed access
PDF file
SZSandra Zetterström
Sandra Zetterström
KHK. Horzmann
K. Horzmann
JYJ. Yin
J. Yin
RMR. Moon
R. Moon
SBS. Boorman
S. Boorman
LBL. Boone
L. Boone

6 November 2020 in Equine Veterinary Education
Verified
Journal Article
Closed access
PDF file
SZSandra Zetterström
Sandra Zetterström
RHR. Hanson
R. Hanson
AAAna Velloso Alvarez
Ana Velloso Alvarez
FCF. Caldwell
F. Caldwell
LBL. Boone
L. Boone
JSJ. Schumacher
J. Schumacher

11 March 2021 in Veterinary Surgery
Verified
Journal Article
Closed access
PDF file
SZSandra Zetterström
Sandra Zetterström
LBLindsey H. Boone
Lindsey H. Boone
KWKathleen M. Weatherall
Kathleen M. Weatherall
FCFred J. Caldwell
Fred J. Caldwell

29 April 2026 in Animals
Verified
Journal Article
Open access
PDF file
AAAna Velloso Alvarez
Ana Velloso Alvarez
AWAnne Wooldridge
Anne Wooldridge
FCFred Caldwell
Fred Caldwell
SZSandra Zetterström
Sandra Zetterström
BMBruno Carvalho Menarim
Bruno Carvalho Menarim
LBLindsey Boone
Lindsey Boone
Synovitis is a key contributor to the development of OA, and early modulation of the synovial environment may help limit downstream cartilage damage. This study compared the clinical and biochemical effects of intra-articular triamcinolone acetonide (TA) and autologous conditioned serum (ACS) in an equine model of IL-1β–induced synovitis. Six healthy adult horses were used in a crossover design involving five groups: PBS (negative control), IL-1β (positive control), IL-1β + ACS, IL-1β + TA, and an exploratory ACS-alone group administered post hoc to isolate its effects without IL-1β interference. Both TA and ACS mitigated inflammation through distinct profiles. TA was superior in reducing joint heat, swelling, and effusion. Conversely, IL-1β + ACS provided greater lameness improvement at 24, 36, and 72 h compared to IL-1β. ACS demonstrated potential chondroprotective advantages, as it did not increase synovial glycosaminoglycan (GAG) concentrations, which were highest in the IL-1β + TA group. ACS treatment resulted in significantly higher synovial total nucleated cell counts and total protein, driven primarily by monocyte enrichment. This cellular profile suggests that ACS may support the restoration of joint homeostasis. While TA remains highly effective for visual inflammatory signs, ACS offers a promising biological alternative for modulating the synovial environment and protecting cartilage during acute synovitis.